Page 6 - Thomas Theuringer News Today

QuantiFERON franchise benefits from new applications, products and automation options, building on strengths in tuberculosis detection while addressing new disease targets QuantiFERON SARS-CoV-2

/PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion...

Easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination Detection of T-cells can provide vital insights that completes the picture

Additional U.S. approval for LIAISON XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin's LIAISON XL analyzer Collaboration now provides full range of automation

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence

QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have reached a settlement in the patent infringement lawsuit related

Press release content from Business Wire. The AP news staff was not involved in its creation.

Q3 2021: Net sales rise 11% (+10% constant exchange rates, CER) to $535 million and adjusted diluted EPS unchanged at $0.58 ($0.58 CER) from Q3 2020, both well above outlook Non-COVID

Easy-to-use cartridge receives CE-marking in Europe and will launch soon Syndromic test differentiates between influenza A and B, RSV and SARS-CoV-2, a critical test for upcoming flu seasons

Relocation expands QIAGEN's global knowledge hub for diagnostics development City has been base of company's pioneering role in Precision Medicine for a decade CityLabs 2.0 facility